Malta - English - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - sulfadiazine - tablet - sulfadiazine 500 mg - antibacterials for systemic use

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - sulfadiazine - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - sulfadiazine - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - sulfadiazine - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - sulfadiazine - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - sulfadiazine - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - sulfadiazine - oral tablet - 500mg

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - sulfadiazine - tablet - sulfadiazine 500 mg - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

eon labs, inc. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, staphylococcus aureus , proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides

United States - English - NLM (National Library of Medicine)

epic pharma, llc - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, staphylococcus aureus, proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups). meningococcal meningitis, when the organism has been demonstrated to be susceptible. acute otitis media due to haemophilus influenzae, when used concomitantly with adequate doses of penicilin. prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. h. influenzae meningitis, as adjunctive therapy with parental streptomycin. important notes in vitro sulfonamide susceptibility tests are not always reliable. the test must be carefully coordinated with bacteriologic and clinical response. when the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. wide variation in blood levels may result with identical doses. blood levels should be measured in patients receiving sulfonamides for serious infections. free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections. twenty mg per 100 ml should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. sulfadiazine is contraindicated in the following circumstances: hypersensitivity to sulfonamides. in infants less than 2 months of age (except as adjunctive therapy with pyrimethamine in the treatment of congenital toxoplasmosis). in pregnancy at term and during the nursing period, because sulfonamides cross the placenta and are excreted in breast milk and may cause kernicterus.